Medullary Thyroid Cancer - Pipeline Insight, 2024

This “Medullary Thyroid Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Medullary Thyroid Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Medullary Thyroid Cancer Understanding

Medullary Thyroid Cancer: Overview

Medullary thyroid cancer, or MTC, is a cancer that forms in the thyroid. The thyroid is a gland located in the front of your neck, just below the Adam’s apple. It is responsible for sending out hormones to the rest of your body. The inside of the thyroid is called the medulla. The medulla contains special cells called parafollicular C cells that produce and release hormones. MTC happens when the C cells become cancerous and grow out of control. MTC may also be called medullary thyroid carcinoma. Thyroid cancer is fairly common. There are four different types of thyroid cancers and MTC is the rarest type making up 3% to 4% of all thyroid cancers. About 1,000 people are diagnosed with MTC each year in the U.S. MTC can start as a lump in the throat. The tumor growing in the thyroid can make your voice hoarse by blocking your vocal chords or it can make it hard to breathe by blocking your windpipe.

Medullary Thyroid Cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Medullary Thyroid Cancer pipeline landscape is provided which includes the disease overview and Medullary Thyroid Cancer treatment guidelines. The assessment part of the report embraces, in depth Medullary Thyroid Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Medullary Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Medullary Thyroid Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Medullary Thyroid Cancer.

Medullary Thyroid Cancer Emerging Drugs Chapters

This segment of the Medullary Thyroid Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Medullary Thyroid Cancer Emerging Drugs

Nivolumab: Bristol-Myers Squibb Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth. Currently, it is in Phase II stage of clinical trial evaluation to treat Medullary ThyroidCancer.

Regorafenib: Bayer Regorafenib is a small-molecule multikinase inhibitor that specifically inhibits epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor-ß (PDGFRB), fibroblast growth factor receptor 1 (FGFR1), and the mutant oncogenic kinases KIT, RET, and B-RAF. Several clinical trials have studied the association between regorafenib response and angiogenesis biomarkers in blood. Higher concentrations of VEGF family ligands, such as PIGF, and lower levels of TIMP2, soluble VEGF receptor 2, and TIE-1 have been associated with the response to regorafenib. A biomarker analysis from the CORRECT clinical trial for regorafenib efficacy in patients with m CRC showed that in both KRAS wild-type and mutant statuses, low levels of circulating free DNA and high levels of TIE-1 in plasma were associated with a clinical benefit. Furthermore, the single-nucleotide polymorphism (SNP) rs2010963 in the VEGF-A gene correlated with an improved PFS and OS in this trial. Thus, genotyping analysis may be useful for the selection of patients who could potentially benefit from regorafenib treatment. Currently, it is in Phase II stage of clinical trial evaluation to treat MedullaryThyroidCancer.

Medullary Thyroid Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Medullary Thyroid Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Medullary Thyroid Cancer

There are approx. 15+ key companies which are developing the therapies for Medullary Thyroid Cancer. The companies which have their Medullary Thyroid Cancer drug candidates in the most advanced stage, i.e. phase II include, Bayer.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Medullary Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Medullary Thyroid Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Medullary Thyroid Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Medullary Thyroid Cancer drugs.

Medullary Thyroid Cancer Report Insights

• Medullary Thyroid Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Medullary Thyroid Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Medullary Thyroid Cancer drugs?
• How many Medullary Thyroid Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medullary Thyroid Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Medullary Thyroid Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Medullary Thyroid Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bristol-Myers Squibb
• Takeda
• Nant Cell,Inc.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Bayer
• Novartis
• Hutchison Medipharma Limited
• Turning Point Therapeutics, Inc.

Key Products

• Nivolumab
• Ponatinib
• GI-6207
• Anlotinib
• HA121-28
• Regorafenib
• Everolimus
• Surufatinib
• TPX-0046

This product will be delivered within 1-3 business days.